Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease results from NHANES 2001 to 2004

Michal L. Melamed, Paul Muntner, Erin D. Michos, Jaime Uribarri, Collin Weber, Jyotirmay Sharma, Paolo Raggi

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Objective-The puipose of this study was to determine the association between 25-hydroxyvitamin D (25(OH)D) levels and the prevalence of peripheral arterial disease (PAD) in the general United States population. Methods and Results-We analyzed data from 4839 participants of the National Health and Nutrition Examination Survey 2001 to 2004 to evaluate the relationship between 25(OH)D and PAD (defined as an ankle-brachial index <0.9). Across quartiles of 25(OH)D, from lowest to highest, the prevalence of PAD was 8.1%, 5.4%, 4.9%, and 3.7% (P trend <0.001). After multivariable adjustment for demographics, comorbidities, physical activity level, and laboratory measures, the prevalence ratio of PAD for the lowest, compared to the highest, 25(OH)D quartile (<17.8 and ≥29.2 ng/mL, respectively) was 1.80 (95% confidence interval: 1.19, 2.74). For each 10 ng/mL lower 25(OH)D level, the multivariable-adjusted prevalence ratio of PAD was 1.35 (95% confidence interval: 1.15, 1.59). Conclusions-Low serum 25(OH)D levels are associated with a higher prevalence of PAD. Several mechanisms have been invoked in the literature to support a potential antiatherosclerotic activity of vitamin D. Prospective cohort and mechanistic studies should be designed to confirm this association. (Arterioscler Thromb Vase Biol. 2008;28:1179-1185)

Original languageEnglish (US)
Pages (from-to)1179-1185
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Nutrition Surveys
Peripheral Arterial Disease
Serum
Confidence Intervals
Ankle Brachial Index
Vitamin D
25-hydroxyvitamin D
Comorbidity
Cohort Studies
Demography
Population

Keywords

  • 25-hydroxyvitamin D
  • Cardiovascular disease
  • Peripheral arterial disease
  • Phosphate
  • PTH

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease results from NHANES 2001 to 2004. / Melamed, Michal L.; Muntner, Paul; Michos, Erin D.; Uribarri, Jaime; Weber, Collin; Sharma, Jyotirmay; Raggi, Paolo.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 28, No. 6, 01.06.2008, p. 1179-1185.

Research output: Contribution to journalArticle

Melamed, Michal L. ; Muntner, Paul ; Michos, Erin D. ; Uribarri, Jaime ; Weber, Collin ; Sharma, Jyotirmay ; Raggi, Paolo. / Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease results from NHANES 2001 to 2004. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2008 ; Vol. 28, No. 6. pp. 1179-1185.
@article{e844dca43e71439a86db99d1e3cdc070,
title = "Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease results from NHANES 2001 to 2004",
abstract = "Objective-The puipose of this study was to determine the association between 25-hydroxyvitamin D (25(OH)D) levels and the prevalence of peripheral arterial disease (PAD) in the general United States population. Methods and Results-We analyzed data from 4839 participants of the National Health and Nutrition Examination Survey 2001 to 2004 to evaluate the relationship between 25(OH)D and PAD (defined as an ankle-brachial index <0.9). Across quartiles of 25(OH)D, from lowest to highest, the prevalence of PAD was 8.1{\%}, 5.4{\%}, 4.9{\%}, and 3.7{\%} (P trend <0.001). After multivariable adjustment for demographics, comorbidities, physical activity level, and laboratory measures, the prevalence ratio of PAD for the lowest, compared to the highest, 25(OH)D quartile (<17.8 and ≥29.2 ng/mL, respectively) was 1.80 (95{\%} confidence interval: 1.19, 2.74). For each 10 ng/mL lower 25(OH)D level, the multivariable-adjusted prevalence ratio of PAD was 1.35 (95{\%} confidence interval: 1.15, 1.59). Conclusions-Low serum 25(OH)D levels are associated with a higher prevalence of PAD. Several mechanisms have been invoked in the literature to support a potential antiatherosclerotic activity of vitamin D. Prospective cohort and mechanistic studies should be designed to confirm this association. (Arterioscler Thromb Vase Biol. 2008;28:1179-1185)",
keywords = "25-hydroxyvitamin D, Cardiovascular disease, Peripheral arterial disease, Phosphate, PTH",
author = "Melamed, {Michal L.} and Paul Muntner and Michos, {Erin D.} and Jaime Uribarri and Collin Weber and Jyotirmay Sharma and Paolo Raggi",
year = "2008",
month = "6",
day = "1",
doi = "10.1161/ATVBAHA.108.165886",
language = "English (US)",
volume = "28",
pages = "1179--1185",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease results from NHANES 2001 to 2004

AU - Melamed, Michal L.

AU - Muntner, Paul

AU - Michos, Erin D.

AU - Uribarri, Jaime

AU - Weber, Collin

AU - Sharma, Jyotirmay

AU - Raggi, Paolo

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Objective-The puipose of this study was to determine the association between 25-hydroxyvitamin D (25(OH)D) levels and the prevalence of peripheral arterial disease (PAD) in the general United States population. Methods and Results-We analyzed data from 4839 participants of the National Health and Nutrition Examination Survey 2001 to 2004 to evaluate the relationship between 25(OH)D and PAD (defined as an ankle-brachial index <0.9). Across quartiles of 25(OH)D, from lowest to highest, the prevalence of PAD was 8.1%, 5.4%, 4.9%, and 3.7% (P trend <0.001). After multivariable adjustment for demographics, comorbidities, physical activity level, and laboratory measures, the prevalence ratio of PAD for the lowest, compared to the highest, 25(OH)D quartile (<17.8 and ≥29.2 ng/mL, respectively) was 1.80 (95% confidence interval: 1.19, 2.74). For each 10 ng/mL lower 25(OH)D level, the multivariable-adjusted prevalence ratio of PAD was 1.35 (95% confidence interval: 1.15, 1.59). Conclusions-Low serum 25(OH)D levels are associated with a higher prevalence of PAD. Several mechanisms have been invoked in the literature to support a potential antiatherosclerotic activity of vitamin D. Prospective cohort and mechanistic studies should be designed to confirm this association. (Arterioscler Thromb Vase Biol. 2008;28:1179-1185)

AB - Objective-The puipose of this study was to determine the association between 25-hydroxyvitamin D (25(OH)D) levels and the prevalence of peripheral arterial disease (PAD) in the general United States population. Methods and Results-We analyzed data from 4839 participants of the National Health and Nutrition Examination Survey 2001 to 2004 to evaluate the relationship between 25(OH)D and PAD (defined as an ankle-brachial index <0.9). Across quartiles of 25(OH)D, from lowest to highest, the prevalence of PAD was 8.1%, 5.4%, 4.9%, and 3.7% (P trend <0.001). After multivariable adjustment for demographics, comorbidities, physical activity level, and laboratory measures, the prevalence ratio of PAD for the lowest, compared to the highest, 25(OH)D quartile (<17.8 and ≥29.2 ng/mL, respectively) was 1.80 (95% confidence interval: 1.19, 2.74). For each 10 ng/mL lower 25(OH)D level, the multivariable-adjusted prevalence ratio of PAD was 1.35 (95% confidence interval: 1.15, 1.59). Conclusions-Low serum 25(OH)D levels are associated with a higher prevalence of PAD. Several mechanisms have been invoked in the literature to support a potential antiatherosclerotic activity of vitamin D. Prospective cohort and mechanistic studies should be designed to confirm this association. (Arterioscler Thromb Vase Biol. 2008;28:1179-1185)

KW - 25-hydroxyvitamin D

KW - Cardiovascular disease

KW - Peripheral arterial disease

KW - Phosphate

KW - PTH

UR - http://www.scopus.com/inward/record.url?scp=44849087389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849087389&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.108.165886

DO - 10.1161/ATVBAHA.108.165886

M3 - Article

C2 - 18417640

AN - SCOPUS:44849087389

VL - 28

SP - 1179

EP - 1185

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 6

ER -